Теродилин

Description

Terodiline is a pharmaceutical substance, N-tert-butyl-1-methyl-3,3-diphenylpropylamine. According to the anatomical-therapeutic-chemical classification, it is assigned to group G - drugs for the treatment of diseases of the genitourinary system. Combines antimuscarinic action with blockade of calcium channels, due to which it reduces detrusor tone. The commercial substance is racemic, hence the designations dl-Terodiline and (±)-Terodiline. Drugs based on it were used for detrusor instability and urinary incontinence and were withdrawn from the market in 1991 after reports of ventricular arrhythmias associated with QT prolongation accumulated.

Basic Attributes

• CAS No: 15793-40-5
• Chemical formula: C20H27N
• Molecular weight: 225.32900 (value given on the product card)
• Exact mass: 281.44 - corresponds to the gross formula C20H27N
• ATC code: G - genitourinary system and sex hormones
• HS code: 2921499090
• PSA specifications: 26.02000
• XLogP3: 4.25610

Physico-chemical characteristics

• Density: 0.956 g/cm3
• Melting point: below 25°C
• Boiling point: 131 °C
• Flash point: 168.9 °C

Pharmacological group and action

Dual mechanism: competitive blockade of muscarinic receptors on bladder smooth muscle and calcium channel antagonism. The result is a decrease in involuntary contractions of the detrusor and an increase in the functional capacity of the bladder. The side effect that determined the fate of the drug is associated with the same calcium-blocking effect: the substance slows down the rhythm and lengthens the corrected QT interval, and the effect depends on the plasma concentration. Terodiline has been shown to increase QTc and QT dispersion in a dose-dependent manner, and cardiotoxicity has been attributed primarily to the R-enantiomer, which suppresses calcium current in cardiomyocytes.

Scope of application

• historical clinical use: detrusor instability, urge urinary incontinence; drugs withdrawn in 1991
• pharmaceutical standard and research object for drug-induced QT prolongation and torsade de pointes (TdP)
• model compound in studies on stereoselective cardiotoxicity and pharmacogenetics of recalled drugs

Storage and transportation conditions

GHS classification and transport codes are not given in the product card. The substance is stored in a tightly closed container in a dry, dark room. Handling - according to the rules for working with pharmaceutical raw materials: local exhaust during weighing, protection of skin and respiratory organs, batch accounting and cross-contamination control.